Biohaven Pharmaceutical Holding Company Ltd.

Equities

BHVN

VGG111961055

Biotechnology & Medical Research

Delayed Nyse 04:00:02 2024-03-28 pm EDT 5-day change 1st Jan Change
54.69 USD -4.09% Intraday chart for Biohaven Pharmaceutical Holding Company Ltd. -2.13% -63.97%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
HC Wainwright Adjusts Biohaven's Price Target to $63 From $50, Maintains Buy Rating MT
TD Cowen Ups Price Target on Biohaven to $55 From $35, Keeps Outperform Rating MT
RBC Trims Price Target on Biohaven to $61 From $62, Keeps Outperform, Speculative Risk MT
Biohaven Q4 Non-GAAP Net Loss Widens, Shares Fall After-Hours MT
RBC Initiates Biohaven at Outperform With Speculative Risk, Sets Price Target at $62, Sees 'Significant Value to Be Unlocked' Over Long Term MT
UBS Adjusts Initiates Biohaven Pharmaceutical Holding With Buy Rating, $59 Price Target MT
Biohaven Insider Sold Shares Worth $459,663, According to a Recent SEC Filing MT
Baird Starts Biohaven Pharmaceutical With Outperform Rating, $58 Price Target MT
JPMorgan Adjusts Biohaven Pharmaceutical Price Target to $32 From $26, Maintains Overweight Rating MT
Piper Sandler Adjusts Price Target on Biohaven Pharmaceutical to $36 From $29, Keeps Overweight Rating MT
Biohaven Pharmaceutical Q3 Net Loss Narrows MT
Biohaven Pharmaceutical Says Obesity Treatment Candidate Reduces Fat, Improves Lean Mass MT
Biohaven Insider Bought Shares Worth $9,999,990, According to a Recent SEC Filing MT
Biohaven Insider Bought Shares Worth $9,999,990, According to a Recent SEC Filing MT
Biohaven Insider Bought Shares Worth $499,994, According to a Recent SEC Filing MT
Biohaven Insider Bought Shares Worth $402,094, According to a Recent SEC Filing MT
Biohaven Pharmaceutical Closes $258.7 Million Public Offering MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Tuesday MT
Biohaven Prices Common Stock Offering at $22 per Share MT
Biohaven Launches $200 Million Share Sale in Public Offering MT
Biohaven Completes Enrollment in Spinal Muscular Atrophy Phase 3 Study of Taldefgrobep Alfa MT
Biohaven Director Buys 50,000 Shares for $922,180 MT
JPMorgan Adjusts Price Target on Biohaven Pharmaceutical Holding to $24 From $27, Maintains Overweight Rating MT
Insider Buy: Biohaven MT
Biohaven Narrows Q2 Non-GAAP Loss; Gets Orphan Drug Label for Taldefgrobep Alfa in Europe MT
Chart Biohaven Pharmaceutical Holding Company Ltd.
More charts
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based commercial-stage biopharmaceutical company. The Company has a portfolio of therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. The Company's Neuroinnovation portfolio includes NURTEC ODT (rimegepant) for the acute and preventive treatment of migraine and a pipeline of product candidates across five platforms: calcitonin gene related peptide (CGRP) receptor antagonism for the acute and preventive treatment of migraine as well as other pain-related disorders and non-migraine indications; glutamate modulation for obsessive-compulsive disorder (OCD); myeloperoxidase (MPO) inhibition for multiple system atrophy (MSA) and amyotrophic lateral sclerosis (ALS); Kv7 Ion Channel Activators (Kv7) to target indications including epilepsy, pain disorders and effective disorders; and Myostatin offers a natural protein that limits skeletal muscle growth.
More about the company
  1. Stock
  2. Equities
  3. Stock Biohaven Pharmaceutical Holding Company Ltd. - Nyse
  4. News Biohaven Pharmaceutical Holding Company Ltd.
  5. Biohaven Pharmaceutical Holding Company Reports Bigger Q2 Loss Despite Higher Revenue